{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-045867","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2026-10-06T12:30:20+00:00","discovered_at":"2026-10-06T12:35:00.262091+00:00","generated_at":"2026-10-12T16:32:01.039683+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"bioAffinity reports CyPath Lung sales up over 100% through Q3 2026","bullets":["CyPath Lung sales rose more than 100% through Q3 2026 versus 2025, with 1,620 tests delivered compared to 775 in Q3 2025.","Ordering physicians increased 89% in Q3 2026 versus Q3 2025; prior prescribers' sales volume rose 48% year-over-year.","CEO Maria Zannes cited a new distribution agreement with Veteran-Owned AvMEDICAL to broaden reach in government healthcare, including the Department of Veterans Affairs.","CyPath Lung reported 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value in high-risk patients with nodules under 20 mm."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-045867","json":"https://secwatch.observer/filing/0001493152-26-045867.json","markdown":"https://secwatch.observer/filing/0001493152-26-045867.md","text":"https://secwatch.observer/filing/0001493152-26-045867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226045867/0001493152-26-045867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226045867/form8-k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T16:32:01.039683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}